LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HORIBA Medical Launches HELO and Yumizen G Range

By LabMedica International staff writers
Posted on 05 Feb 2018
Print article
Image: The G800 coagulation analyzer (Photo courtesy of HORIBA Medical).
Image: The G800 coagulation analyzer (Photo courtesy of HORIBA Medical).
HORIBA Medical (Montpellier, France) showcased and launched the HELO island configuration solution and the new Yumizen G Range of coagulation analyzers at MEDLAB Middle East, the world’s largest attended laboratory and IVD exhibition and conference.
 
HORIBA Medical is one of the five segments of the Japanese HORIBA Group and one of the global leaders in the hematology market. At the MEDLAB Middle East 2018 held from February 5-8, 2018 in Dubai, UAE, the company showcased HELO (HORIBA Evolutive Laboratory Organization), an innovative design solution covering all the needs of high throughput automated hematology platforms. The HELO solution is based on four fundamentals pillars: using reference methods to count cells, simplifying the user interface with its solution, consider tube workflow management differently from the competition and purpose a scalable solution to fit laboratory needs. With features such as high throughput of 120 samples per hour, automatic slide maker/stainer, comprehensive automated slide digitalization, automated conveyor with multi possible configurations, hematology middleware and expert validation station, HELO provides the optimum answer to the constant evolution of the laboratory.
 
HORIBA Medical also showcased the new Yumizen G Range of coagulation analyzers, which includes the Yumizen G1550, Yumizen G800, Yumizen G400, Yumizen G200 and Yumizen G100. The Yumizen G100 is the smallest analyzer for point of care laboratories to monitor oral anticoagulant, whereas the Yumizen G1550 is a fully automated, high-capacity coagulation analyzer to manage the diagnostic and monitoring requirements of clinical laboratories with mid to high workload. 
 
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more